Routine medical tests crucial for detecting and monitoring cancer and different conditions plummeted in the U.S. since mid-March, as the coronavirus spread and public officials urged residents to stay-at-home, in line with a new report by Komodo Health.
Diagnostic panels and cancer screenings usually performed throughout annual physician visits dropped by up to 68% nationally, and by even more in coronavirus hotspots.
These tests, workplace visits, surgical procedures, and other medical care tied to them are key sources of income for hospitals and healthcare techniques that needed to curb profitable elective procedures to guarantee room for a crush of sufferers with COVID-19, the sickness attributable to the brand new coronavirus.
Hundreds of thousands of sufferers postponed exams thought of essential for detecting early indicators of disease, monitoring its development, and improving patient outcomes in response to Komodo, which has one of the nation’s largest medical claims database.
Cervical cancer screenings had been down 68%, cholesterol panels fell by 67%, and the blood sugar test to detect diabetes had been off 65% nationally. This might all prove very expensive down the road.
San Francisco-based Komodo reviewed billing records of 320 million sufferers across the nation from March 19 to April 20 and in contrast it to the preceding 11 weeks and a similar interval last year.